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Acute and Late Outcomes of the Multicenter Canadian Experience
Josep Rodés-Cabau, MD,* John G. Webb, MD,† Anson Cheung, MD,† Jian Ye, MD,†
Eric Dumont, MD,* Christopher M. Feindel, MD,‡ Mark Osten, MD,‡ Madhu K. Natarajan, MD,§
James L. Velianou, MD,§ Giuseppe Martucci, MD, Benoît DeVarennes, MD,
Robert Chisholm, MD,¶ Mark D. Peterson, MD,¶ Samuel V. Lichtenstein, MD,†
Fabian Nietlispach, MD,† Daniel Doyle, MD,* Robert DeLarochellière, MD,* Kevin Teoh, MD,§
Victor Chu, MD,§ Adrian Dancea, MD, Kevin Lachapelle, MD, Asim Cheema, MD,¶
David Latter, MD,¶ Eric Horlick, MD‡
Quebec City and Montreal, Quebec; Vancouver, British Columbia; and
Toronto and Hamilton, Ontario, Canada
Objectives The aim of this study was: 1) to evaluate the acute and late outcomes of a transcatheter aortic valve implanta-
tion (TAVI) program including both the transfemoral (TF) and transapical (TA) approaches; and 2) to determine
the results of TAVI in patients deemed inoperable because of either porcelain aorta or frailty.
Background Very few data exist on the results of a comprehensive TAVI program including both TA and TF approaches for the
treatment of severe aortic stenosis in patients at very high or prohibitive surgical risk.
Methods Consecutive patients who underwent TAVI with the Edwards valve (Edwards Lifesciences, Inc., Irvine, California)
between January 2005 and June 2009 in 6 Canadian centers were included.
Results A total of 345 procedures (TF: 168, TA: 177) were performed in 339 patients. The predicted surgical mortality (Soci-
ety of Thoracic Surgeons risk score) was 9.8  6.4%. The procedural success rate was 93.3%, and 30-day mortality
was 10.4% (TF: 9.5%, TA: 11.3%). After a median follow-up of 8 months (25th to 75th interquartile range: 3 to 14
months) the mortality rate was 22.1%. The predictors of cumulative late mortality were peri-procedural sepsis (hazard
ratio [HR]: 3.49, 95% confidence interval [CI]: 1.48 to 8.28) or need for hemodynamic support (HR: 2.58, 95% CI:
1.11 to 6), pulmonary hypertension (PH) (HR: 1.88, 95% CI: 1.17 to 3), chronic kidney disease (CKD) (HR: 2.30, 95%
CI: 1.38 to 3.84), and chronic obstructive pulmonary disease (COPD) (HR: 1.75, 95% CI: 1.09 to 2.83). Patients with
either porcelain aorta (18%) or frailty (25%) exhibited acute outcomes similar to the rest of the study population, and
porcelain aorta patients tended to have a better survival rate at 1-year follow-up.
Conclusions A TAVI program including both TF and TA approaches was associated with comparable mortality as predicted by
surgical risk calculators for the treatment of patients at very high or prohibitive surgical risk, including porcelain
aorta and frail patients. Baseline (PH, COPD, CKD) and peri-procedural (hemodynamic support, sepsis) factors
but not the approach determined worse outcomes. (J Am Coll Cardiol 2010;55:1080–90) © 2010 by the
American College of Cardiology Foundation
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March 16, 2010:1080–90 TAVI: Multicenter Canadian Experienceranscatheter aortic valve implantation (TAVI) has emerged
s an alternative to surgical aortic valve replacement (SAVR)
or patients with symptomatic severe aortic stenosis considered
o be at very high or prohibitive operative risk (1–6). Both the
ransfemoral (TF) and transapical (TA) approaches have been
sed for TAVI with the Edwards valve system (Edwards
ifesciences, Inc., Irvine, California) (1–5). Patients have
sually been evaluated for TAVI in the setting of a program
ncluding interventional cardiology and cardiac surgery teams,
ith the selection of 1 approach over the other on the basis of
he size and/or disease of iliofemoral arteries. However, most
tudies have evaluated the results of TAVI separately according
o the approach (TF vs. TA) used, and very few single-center
eries have determined the results of a global TAVI program
ncluding both approaches for the treatment of symptomatic
evere aortic stenosis (7–9).
See page 1091
The TAVI technology has been mostly applied in very
ld patients with a high number of comorbidities (1–9).
perative risk score calculators (i.e., logistic EuroSCORE,
arsonett score, Society of Thoracic Surgeons Predicted
isk of Mortality [STS-PROM] score) that take into
onsideration the most important patient comorbidities
ave been used to determine which patients are at very high
r prohibitive surgical risk. However, many elderly patients
re deemed inoperable on the basis of comorbidities not
ncluded in surgical risk calculators (10). Therefore, a high
roportion of patients have been refused for SAVR and
ave undergone TAVI on the basis of risk factors such as
orcelain aorta or frailty (1–9), neither of which is included
n the surgical risk calculators. To date, the safety and
fficacy of TAVI procedures have been measured by com-
aring the procedural and 30-day results with predicted
perative mortality as calculated by surgical risk calculators,
ut no studies have determined the results of TAVI in
atients with porcelain aorta or frailty, 2 of the most
requent comorbidities in elderly patients with severe aortic
tenosis not included in the surgical risk scores. The
bjectives of this multicenter study were: 1) to evaluate the
cute and midterm follow-up results and prognostic factors
f a comprehensive TAVI program including both the TF
nd TA approaches for the treatment of severe aortic
tenosis in patients at very high or prohibitive surgical risk;
nd 2) to determine the results of this TAVI program in
atients deemed inoperable because of either porcelain aorta
r frailty.
ethods
n 2005, the Canadian TAVI program was approved by the
epartment of Health and Welfare (Ottawa, Ontario,
anada) for compassionate clinical use in patients with
ymptomatic severe aortic stenosis considered nonoperable
r very high surgical risk candidates. All consecutive iatients who underwent TAVI
etween January 2005 and June
009 in 6 Canadian centers with
he Cribier-Edwards, Edwards-
APIEN or SAPIEN XT valve
Edwards Lifesciences) in the
etting of the Canadian compas-
ionate clinical use program were
ncluded. All potential candi-
ates for TAVI were evaluated
y a multidisciplinary team com-
osed of interventional cardiolo-
ists and cardiac surgeons who
etermined the eligibility of the
atient for TAVI. Patients consid-
red eligible for TAVI underwent
systematic workup protocol that
ncluded Doppler echocardiogra-
hy, coronary angiography, aorto-
liofemoral angiography, and com-
uted tomography. Depending on
he size, disease, and degree of
alcification of iliofemoral arteries
he patients were selected for TF
r TA approach. Starting in May
007, all cases were presented, discussed, and finally approved
or TAVI (TF or TA approach) in a weekly conference call
ncluding interventional cardiologists and cardiac surgeons of
articipating centers. Patients’ comorbidities were defined with
he STS risk score definitions. Pulmonary hypertension (PH)
as defined as a pulmonary systolic pressure 60 mm Hg as
stimated by Doppler echocardiography or measured by
ardiac catheterization. Frailty was defined as a syndrome of
ecreased reserve and resistance to stressors, resulting from
ultiple declines across multiple physiologic systems lead-
ng to vulnerability to adverse outcomes (11). No systematic
ests were performed for the evaluation of frailty, and
atients were considered nonoperable because of frailty
ainly on the basis of the criteria of the medical team
valuating them. Indeed, at least 2 cardiac surgeons had to
gree when frailty was the main criterion determining
noperability, and the specific reasons for the decision had to
e detailed during the weekly conference call. Porcelain
orta was defined as an extensive circumferential calcifica-
ion of the thoracic aorta as assessed by computed tomog-
aphy and/or fluoroscopy. Baseline clinical and echocardi-
graphy data were prospectively gathered in each
articipating center. All patients provided written informed
onsent for the procedures.
rocedures and 30-day outcomes. The TF and TA proce-
ures were performed as previously described (1–5). The Edwards
alve (Cribier-Edwards, Edwards-SAPIEN, SAPIEN XT) was
sed in all cases. The 23-mm valve was implanted if the trans-
sophageal echocardiographic measurement of the aortic annulus
as between 17 and 21 mm, and the 26-mm valve was implanted
Abbreviations
and Acronyms
CI  confidence interval
CKD  chronic kidney
disease
COPD  chronic
obstructive pulmonary
disease
HR  hazard ratio
MI  myocardial infarction
MR  mitral regurgitation
OR  odds ratio
PH  pulmonary
hypertension
SAVR  surgical aortic
valve replacement
STS-PROM  Society of
Thoracic Surgeons
Predicted Risk of Mortality
TA  transapical
TAVI  transcatheter aortic
valve implantation
TF  transfemoralf the aortic annulus measured between 22 and 25 mm.
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TAVI: Multicenter Canadian Experience March 16, 2010:1080–90Procedural success was defined as the implantation
f a functioning valve within the aortic annulus, without
ntraprocedural mortality. Major procedural complica-
ions included valve embolization, need for a second
alve, need for hemodynamic support with balloon coun-
erpulsation or femoral-femoral extracorporeal circula-
ion, conversion to open heart surgery, major access site
omplications, and life-threatening arrhythmias. Major
ccess site complications were defined as those leading to
ither severe bleeding requiring blood transfusion, fatal
leeding, or need for surgical or transcatheter repair. In
he TA approach, both the occurrence of myocardial tears
equiring further surgical repair and accidental damage of
coronary artery during apical repair were also consid-
red major access complications. Major post-procedural
30-day) complications included stroke, myocardial in-
arction, sepsis, need for hemodialysis, and need for a
ermanent pacemaker. Doppler-echocardiography was
erformed at hospital discharge in all patients who
urvived the procedure. Procedural and 30-day events and
chocardiographic data were prospectively recorded in
ach of the participating centers. After the procedure
atients received aspirin (80 mg/day) indefinitely and
lopidogrel (75 mg/day) for 3 to 6 months.
ollow-up. Clinical follow-up was carried out in clinical
isits and/or through phone contact. The timing and
requency of the clinical follow-up was determined by each
articipating center. Most patients were followed at 6
onths to 1 year after the procedure and annually thereaf-
er. Death and re-intervention at any time during the
ollow-up period were recorded.
tatistical analysis. Qualitative variables were expressed as
ercentages, and quantitative variables were expressed as
ean (SD) or median (25th to 75th interquartile range).
omparison of numerical variables was performed with the
tudent t test or Wilcoxon rank sum test, depending on
ariable distribution. The chi-square test or Fischer’s exact
est was used to compare qualitative variables. Procedural
nd outcome results of TF and TA approaches are provided
ut not compared, due to the differences in baseline char-
cteristics between groups. A stepwise logistic regression
nalysis including all variables with p value 0.2 in the
nivariate analysis was used to determine the predictive
actors of 30-day mortality. A Cox multivariate analysis
ncluding all variables with p value 0.2 in the Cox
nivariate analysis was used to determine the predictive
actors of cumulative late mortality. Survival rates up to 2
ears were presented as Kaplan-Meier curves, and the
og-rank test was used for comparison between patients with
orcelain aorta and frailty and the rest of the study popu-
ation. Differences were considered statistically significant at
values0.05. The data were analyzed with SAS statistical
oftware version 9.1.3 (SAS Institute, Inc., Cary, North
arolina). tesults
total of 396 patients were considered potential candidates
or TAVI by the multidisciplinary team of each center. Of
hese, 5 patients were turned down during the weekly
onference call (of 291 patients presented since May 2007)
nd 52 patients were included in the PARTNER (Place-
ent of AoRTic TraNscathetER Valve) trial, leading to a
nal study population of 339 patients who underwent TAVI
nder the Canadian compassionate clinical use TAVI pro-
ram (Fig. 1). One-hundred sixty-seven patients (49.6%)
ere selected for TF approach, and 172 patients (50.7%)
ere selected for TA approach. Six patients who had had
nsuccessful TF procedure underwent a second TA (n  5)
r TF (n  1) procedure later on, leading to a total of 345
AVI procedures (168 TF, 49%; 177 TA, 51%). Baseline
linical and echocardiographic characteristics of the study
opulation are shown in Table 1.
rocedural and 30-day outcomes. Procedural and 30-day
utcomes are shown in Table 2. The procedure was suc-
essful in 322 (93.3%) cases. Procedural, post-procedural,
nd cumulative 30-day mortality were 1.7% (n  6), 8.7%
n  30), and 10.4% (n  36), respectively. Reasons for
nsuccessful procedure were at least 1 of the following:
alloon instability during aortic balloon valvuloplasty that
recluded valve implantation attempt (n  1, 0.3%), inabil-
ty to advance the delivery catheter through iliofemoral
rteries (n  5, 1.4%), major vascular complications (n  2,
.6%), inability to cross the native aortic valve (n  5,
.4%), valve embolization with no implantation of a second
alve (n  6, 1.7%), and procedural death (n  6, 1.7%).
he reasons leading to procedural death were major vascular
omplications (n 2, 0.6%), severe left ventricular dysfunc-
ion after valve implantation (n  2, 0.6%), cardiac perfo-
ation (n  1, 0.3%), and acute severe MR after balloon
alvuloplasty (n  1, 0.3%). Major access site complications
ere the most frequent procedural complication (45 cases,
3%) and occurred in TF (22 cases, 13.1%) and TA (23
ases, 13.0%) cases. Valve embolization occurred in 7
rocedures (2%), and a second valve was implanted in 9
rocedures (2.6%) because of valve embolization, valve
alposition, and/or severe transvalvular or peri-valvular
rosthetic regurgitation. A total of 14 patients (4.1%)
eeded hemodynamic support with aortic balloon counter-
ulsation (n  3, 0.9%) or extracorporeal circulation (n 
0, 2.9%) or both (n  1, 0.3%), due to severe maintained
ypotension or hemodynamic collapse secondary to acute
evere left ventricular dysfunction (n  10, 2.9%), ventric-
lar apical bleeding (n  3, 0.9%), or cardiac perforation
n  1, 0.3%).
A total of 30 patients (8.7%) died within the 30 days
fter TAVI. The causes of death for these patients were:
ultiorgan failure (n  6, 1.7%), major bleeding (n  5,
.4%), pneumonia/septicemia (n  4, 1.2%), stroke (n 
, 0.6%), ventricular arrhythmia (n  2, 0.6%), conges-
ive heart failure (n  2, 0.6%), cardiogenic shock (n  1,
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March 16, 2010:1080–90 TAVI: Multicenter Canadian Experience.3%), sudden unexplained death (n  2, 0.6%), myocar-
ial infarction (n  1, 0.3%), late (48 h) ventricular
mbolization of the valve leading to cardiogenic shock
n  1, 0.3%), pulmonary embolism (n  1, 0.3%),
eripheral embolism (n  1, 0.3%), aortic rupture (n  1,
.3%), and severe mitral regurgitation (MR) likely sec-
ndary to mitral leaflet perforation (n  1, 0.3%). The
linical and procedural characteristics of the patients who
ied within 30 days after TAVI compared with those
ho survived are shown in Table 3. The predictive factors
f cumulative 30-day mortality identified by multivariate
nalysis were PH (odds ratio [OR]: 2.09, 95% confidence
nterval [CI]: 1.02 to 4.43, p  0.048), severe MR (OR:
.01, 95% CI: 1.09 to 8.24, p  0.033), and the need for
eri-procedural hemodynamic support (OR: 6.84, 95%
I: 2.04 to 22.93, p  0.002).
Mean aortic gradient and aortic valve area decreased and
ncreased, respectively, from 46  17 mm Hg and 0.63 
.17 cm2 at baseline to 10 4 mm Hg and 1.55 0.41 cm2
t discharge (p 0.0001 for both). Most patients (84%) had
ome degree of residual aortic regurgitation at hospital
Figure 1 Canadian Transcatheter Aortic Valve Implantation Pro
Flow chart showing the patients who underwent transcatheter aortic valve implanta
of the Canadian compassionate clinical use program. PARTNER  Placement of Aischarge (trivial or mild: 78%; moderate: 5%; severe: 1%). sorcelain aorta and frail patients. Porcelain aorta was
resent in 61 patients (18%). Baseline and procedural
haracteristics of patients with porcelain aorta are shown in
able 4. Patients with porcelain aorta were younger; were
ore frequently female; exhibited a lower STS-PROM
core and creatinine values; and had a lower prevalence of
erebrovascular disease, PH, and severe MR. Approximately
ne-half of the patients with porcelain aorta underwent
AVI by TF approach. The procedure was successful in
8.4% of the patients, but valve malposition requiring the
mplantation of a second valve tended to be more frequent
n these patients. The stroke and 30-day mortality rate were
.6% and 11.5%, respectively, with no differences compared
ith patients without porcelain aorta. Frailty was a comor-
idity in 85 patients (25%). Baseline and procedural char-
cteristics of frail patients are shown in Table 4. Frail
atients were older and more frequently women, exhibited a
ower weight and body mass index, and were associated with
higher STS-PROM score and a lower rate of prior
ABG. Procedural and 30-day mortality rates (2.4% and
.2%, respectively) were similar to that of the rest of the
AVI) on the basis
raNscathetER Valve trial.gram
tion (T
oRTic Ttudy population, but frail patients more frequently devel-
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TAVI: Multicenter Canadian Experience March 16, 2010:1080–90ped acute renal failure requiring hemodialysis in the
ost-operative period.
ate outcomes. Clinical follow-up was available in all
atients at a median of 8 months (25th to 75th inter-
uartile range: 3 to 14 months) after TAVI. A total of 39
atients (11.5%) died during the follow-up period, at a
edian of 162 days (25th to 75th interquartile range: 72
o 390 days) after the TAVI procedure. Of these, 26
atients (7.7%) died of noncardiac causes (respiratory 
3, hemorrhagic or ischemic stroke  3, renal failure 
, cancer  2, cachexy  2, amyotrophic lateral sclerosis
1, pancreatitis  1, subdural hematoma  1). The
aseline and procedural characteristics of the patients
ho died during the follow-up period compared with
hose who survived are shown in Table 5. The predictors
f cumulative late mortality were post-procedural sepsis
hazard ratio [HR]: 3.49, 95% CI: 1.48 to 8.28), need for
eri-procedural hemodynamic support (HR: 2.58, 95%
I: 1.11 to 6), PH (HR: 1.88, 95% CI: 1.17 to 3),
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Variables
All Patients
(n  339)
Age (yrs) 81 8
Male sex 152 (44.8)
BMI (kg/m2) 26 5
Diabetes 79 (23.3)
Dyslipidemia 241 (71.1)
Hypertension 252 (74.3)
Current smokers 20 (5.9)
NYHA functional class
I–II 29 (8.6)
III–IV 308 (90.9)
Chronic atrial fibrillation/flutter 115 (33.9)
Coronary artery disease 234 (69.0)
Previous myocardial infarction 173 (51.0)
Previous PCI 99 (29.2)
Prior coronary artery bypass grafting 116 (34.2)
Cerebrovascular disease 77 (22.7)
Peripheral vascular disease 120 (35.4)
COPD 100 (29.5)
Creatinine (mol/l) 119 83
eGFR 60 ml/min 191 (56.3)
Dialysis 10 (2.9)
STS-PROM score (%) 9.8 6.4
Porcelain aorta 61 (17.9)
Frailty 85 (25.1)
Pulmonary hypertension 84 (25.0)
Severe mitral regurgitation 27 (8.0)
Mean aortic gradient (mm Hg) 46 17
Aortic valve area (cm2) 0.63 0.17
LVEF (%) 55 14
LVEF 40% 54 (15.9)
Values are expressed as n (%) or mean  SD.
BMI body mass index; COPD chronic obstructive pulmonary d
ejection fraction; NYHA New York Heart Association; PCI percu
Predicted Risk Of Mortality.hronic kidney disease [CKD] (HR: 2.30, 95% CI: 1.38 ao 3.84), and chronic obstructive pulmonary disease
COPD] (HR: 1.75, 95% CI: 1.09 to 2.83). Figure 2
hows the Kaplan-Meier survival curves for the entire
tudy population and for the TF and TA groups. Survival
ates at 1- and 2-year follow-up were, respectively, 76%
95% CI: 71% to 82%) and 64% (95% CI: 56% to 74%)
or the entire study population; 75% (95% CI: 68% to
2%) and 65% (95% CI: 53% to 75%) for the TF group;
nd 78% (95% CI: 71% to 85%) and 64% (95% Cl: 52%
o 80%) for the TA group. The percentage of patients
ree of death, MI, or stroke at 1- and 2- year follow-up
ere, respectively, 72% (95% CI: 67% to 78%) and 60%
95% CI: 53% to 71%) for the entire study population;
3% (95% CI: 65% to 81%) and 63% (95% CI: 52% to
5%) for the TF group, and 72% (95% CI: 65% to 81%)
nd 59% (95% CI: 47% to 75%) for the TA group. Figure
shows the Kaplan-Meier survival curves for patients
ith porcelain aorta or frailty as comorbidities. Patients
ith porcelain aorta tended to have a better survival rate
339)pulation (n  339)
Transfemoral
(n  162)
Transapical
(n  177) p Value
83 8 80 8 0.009
91 (56.1) 61 (34.5) 0.0001
26 5 26 5 0.934
37 (22.8) 42 (23.7) 0.898
104 (64.2) 137 (77.4) 0.020
102 (62.9) 150 (84.7) 0.0001
8 (4.9) 12 (6.8) 0.645
11 (6.8) 18 (10.2) 0.332
150 (92.6) 158 (89.3)
66 (40.7) 49 (27.7) 0.012
110 (67.9) 124 (70.1) 0.723
82 (50.6) 91 (51.4) 0.913
47 (29.0) 52 (29.4) 1.00
49 (30.2) 67 (37.9) 0.169
27 (16.7) 50 (28.2) 0.013
31 (19.1) 89 (50.3) 0.0001
45 (27.8) 55 (31.1) 0.551
124 85 113 81 0.232
86 (53.1) 104 (58.8) 0.325
7 (4.3) 3 (1.7) 0.203
9.0 5.8 10.5 6.9 0.034
28 (17.3) 33 (18.6) 0.779
42 (25.9) 43 (24.3) 0.802
35 (21.6) 49 (27.7) 0.256
18 (11.1) 9 (5.1) 0.045
48 18 44 17 0.079
0.63 0.16 0.63 0.18 0.928
55 14 56 14 0.721
26 (16.1) 28 (15.8) 1.00
eGFR estimated glomerular filtration rate; LVEF left ventricular
s coronary intervention; STS-PROM Society of Thoracic Surgeonsn (n dy Po
isease;t 1-year follow-up (86%, 95% CI: 77% to 95% vs. 74%,
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March 16, 2010:1080–90 TAVI: Multicenter Canadian Experience5% CI: 68% to 80%, p  0.14). There were no cases of
tructural valve dysfunction at follow-up, and only 1
atient required SAVR at 8-month follow-up due to
ndocarditis.
iscussion
his multicenter study including a large series of patients
iagnosed with severe symptomatic aortic stenosis deemed
noperable or at very high surgical risk showed that a global
AVI program including both TF and TA approaches was
ssociated with a 30-day mortality of 10.4% and a cumula-
ive mortality rate of 22.1% after a mean follow-up of nearly
year. The characteristics of the population and the size of
he catheters determined the greater use of the TA ap-
roach, which was undertaken in more than one-half of the
atients. The presence of severe PH and severe MR but not
he STS-PROM score were predictive factors of 30-day
ortality. The procedural variable associated with 30-day
ortality was any complication leading to the need for
emodynamic support. Predictive factors of cumulative late
ortality were peri-procedural need for hemodynamic sup-
ort, post-procedural sepsis, PH, COPD, and CKD. The
AVI approach (TF vs. TA) had no prognostic value in
cute and late outcomes. Patients diagnosed with porcelain
orta or frailty had similar 30-day and late results compared
ith the rest of the study population. Porcelain aorta
atients were associated with a relatively low risk of peri-
rocedural and 30-Day OutcomesTable 2 Procedural and 30-Day Outcomes
Variables
All
Procedures
(n  345)
Transfemoral
(n  168)
Transapical
(n  177)
Procedural variables
Successful procedure 322 (93.3) 152 (90.5) 170 (96.1)
Procedural death 6 (1.7) 3 (1.8) 3 (1.7)
Valve embolization 7 (2.0) 5 (3.0) 2 (1.1)
Need for a second
valve
9 (2.6) 4 (2.4) 5 (2.8)
Conversion to open
heart surgery
6 (1.7) 2 (1.2) 4 (2.3)
Need for hemodynamic
support
14 (4.1) 7 (4.2) 7 (3.9)
Major access site
complications
45 (13.0) 22 (13.1) 23 (13.0)
Stroke 2 (0.6) 1 (0.6) 1 (0.6)
Coronary obstruction 3 (0.9) 1 (0.6) 2 (1.1)
Life-threatening
arrhythmias
28 (8.1) 12 (7.1) 16 (9.0)
30-day outcomes
Myocardial infarction 4 (1.2) 1 (0.6) 3 (1.7)
Stroke 8 (2.3) 5 (3.0) 3 (1.7)
Sepsis 10 (2.9) 5 (3.0) 5 (2.8)
Need for hemodialysis 9 (2.6) 3 (1.8) 6 (3.4)
Need for permanent
pacemaker
17 (4.9) 6 (3.6) 11 (6.2)
30-day mortality 36 (10.4) 16 (9.5) 20 (11.3)
alues are expressed as n (%).rocedural stroke (1.6%), although with a wide CI, and
Vhose who survived the procedure also tended to have a
ower risk of death at 1-year follow-up.
AVI global program including TF and TA approaches.
he retrograde TF approach has become the approach of
hoice for TAVI. The TA approach appeared as a comple-
entary option for those who were noncandidates for the TF
linical and Peri-Procedural Characteristics of theatients, Acco ding to the Occu rence of0-Day Mortality
Table 3
Clinical an Peri-Proc dural Charact ristics of the
Patients, According to the Occurrence of
30-Day Mortality
30-Day Mortality
Variables
Yes
(n  36)
No
(n  303) p Value
Baseline
Age (yrs) 81 9 81 8 0.836
Male sex 17 (47.2) 135 (44.6) 0.721
BMI (kg/m2) 25 4 26 5 0.399
Diabetes 6 (16.7) 73 (24.1) 0.407
Dyslipidemia 21 (58.3) 220 (72.7) 0.109
Hypertension 26 (72.2) 226 (74.6) 1.00
Current smokers 2 (5.6) 18 (5.9) 1.00
Chronic atrial fibrillation/flutter 13 (36.1) 102 (33.7) 0.709
Coronary artery disease 25 (69.4) 209 (69.0) 0.849
Previous myocardial infarction 23 (63.9) 150 (49.5) 0.077
Previous PCI 10 (27.8) 89 (29.4) 1.00
Prior coronary artery bypass
grafting
10 (27.8) 106 (34.9) 0.460
Cerebrovascular disease 11 (30.6) 66 (21.8) 0.206
Peripheral vascular disease 13 (36.1) 107 (35.3) 0.854
COPD 12 (33.3) 88 (29.1) 0.559
Creatinine (mol/l) 136 89 117 82 0.201
eGFR 60 ml/min 27 (75.0) 163 (53.8) 0.020
Dialysis 1 (2.8) 9 (2.9) 1.00
STS score (%) 10.3 6.3 9.8 6.5 0.609
Porcelain aorta 7 (19.4) 54 (17.8) 0.819
Frailty 7 (19.4) 78 (25.7) 0.542
Pulmonary hypertension 14 (38.9) 70 (23.1) 0.039
Severe mitral regurgitation 6 (16.7) 21 (7.0) 0.049
LVEF (%) 55 15 55 14 0.866
LVEF 40% 7 (19.4) 47 (15.5) 0.629
Procedural and 30-day outcome
variables
Approach
Transfemoral 16 (44.4) 146 (48.2) 0.726
Transapical 20 (55.6) 157 (51.8)
Unsuccessful procedure* 2 (6.7) 10 (3.3) 0.295
Valve embolization 2 (5.6) 5 (1.6) 0.164
Need for a second valve 2 (5.6) 7 (2.3) 0.246
Conversion to open heart
surgery
3 (8.3) 3 (0.9) 0.018
Need for hemodynamic support 5 (13.9) 9 (2.9) 0.010
Major access site complications 9 (25.0) 36 (11.9) 0.038
Life-threatening arrhythmias 5 (13.9) 23 (7.6) 0.199
Myocardial infarction 2 (5.6) 2 (0.7) 0.057
Stroke 2 (5.6) 6 (1.9) 0.204
Sepsis 3 (8.3) 7 (2.3) 0.078
Need for hemodialysis 1 (2.8) 8 (2.6) 1.00
Need for permanent pacemaker 1 (2.8) 16 (5.3) 1.00alues are expressed as n (%) or mean  SD. *Excluding procedural death.
Abbreviations as in Table 1.
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valuated its role in a global TAVI program (7–9). The present
tudy showed that the TA approach made it possible to treat
ore than one-half of the potential TAVI candidates, high-
ighting the relevance of this approach in a TAVI program.
aseline Characteristics, 30-Day, and Late Outcomes, According toTable 4 Baseline Characteristics, 30-Day, and Late Outcomes,
Porcelain Aort
Variables
No
(n  278)
Yes
(n  61)
Age (yrs) 82 8 78 8
Male sex 137 (49.3) 15 (24.6)
BMI (kg/m2) 26 5 26 5
Weight (kg) 69.3 15.2 66.8 15.
Height (cm) 164.2 10.8 161.4 8.3
Diabetes 68 (24.5) 11 (18.0)
Dyslipidemia 189 (68.0) 52 (85.3)
Hypertension 215 (77.3) 37 (60.7)
Current smokers 16 (5.8) 4 (6.6)
Chronic atrial fibrillation/flutter 101 (36.3) 14 (22.9)
Coronary artery disease 191 (68.7) 43 (70.5)
Previous myocardial infarction 141 (50.7) 32 (52.5)
Previous PCI 83 (30.0) 16 (26.2)
Prior coronary artery bypass grafting 98 (35.3) 18 (29.5)
Cerebrovascular disease 71 (25.5) 6 (9.8)
Peripheral vascular disease 93 (33.5) 27 (44.3)
COPD 84 (30.2) 16 (26.2)
Creatinine (mol/l) 124 89 92 37
eGFR 60 ml/min 161 (57.9) 29 (47.5)
Dialysis 10 (3.6) 0
STS-PROM score (%) 10.2 6.6 7.9 5.6
Pulmonary hypertension 75 (27.0) 9 (14.8)
Severe mitral regurgitation 19 (6.8) 8 (13.1)
LVEF (%) 55 15 57 11
LVEF 40% 48 (17.3) 6 (9.8)
Procedural and 30-day outcomes
Approach
Transfemoral 134 (48.2) 28 (45.9)
Transapical 144 (51.8) 33 (54.1)
Successful procedure 261 (93.9) 60 (98.4)
Procedural death 6 (2.2) 0
Valve embolization 6 (2.2) 1 (1.6)
Need for a second valve 5 (1.8) 4 (6.6)
Conversion to open heart surgery 4 (1.4) 2 (3.2)
Need for hemodynamic support 11 (3.9) 3 (4.9)
Major access site complications 35 (12.6) 10 (16.4)
Life-threatening arrhythmias 22 (7.9) 6 (9.8)
Myocardial infarction 4 (1.4) 0
Stroke 7 (2.5) 1 (1.6)
Sepsis 9 (3.2) 1 (1.6)
Need for hemodialysis 9 (3.2) 0
Permanent pacemaker 12 (4.3) 5 (8.2)
30-day mortality 29 (10.4) 7 (11.5)
Late outcomes
Follow-up length (months) 9.8 8.3 10.7 7.7
Cumulative mortality 65 (23.4) 10 (16.4)
alues are expressed as n (%) or mean  SD.
Abbreviations as in Table 1.ccording to our results, previous reports from single centers aith the 2 approaches showed that 32% to 52% of the patients
ere treated by TA approach (7–9). Interestingly, we have
reviously shown that a global TAVI program allowed the
reatment of up to 76% of the patients refused for SAVR (7).
ore recently, Himbert et al. (8) showed that having the TF
Presence of Porcelain Aorta or Frailtyrding to the Presence of Porcelain Aorta or Frailty
Frailty
p Value
No
(n  254)
Yes
(n  85) p Value
0.001 81 7 83 7 0.008
0.0001 125 (47.2) 27 (31.8) 0.005
0.927 26 5 25 5 0.023
0.254 70.4 15.4 64.1 14.3 0.0009
0.029 164.5 10.6 161.3 9.7 0.014
0.319 58 (23.0) 21 (26.6) 0.768
0.012 186 (73.2) 55 (65.5) 0.121
0.009 194 (76.4) 58 (68.2) 0.114
0.759 17 (6.7) 3 (3.6) 0.426
0.052 82 (32.3) 33 (38.8) 0.293
0.879 177 (69.7) 57 (67.1) 0.588
0.888 134 (52.8) 39 (45.9) 0.261
0.642 73 (28.7) 26 (30.6) 0.784
0.457 96 (37.8) 20 (23.5) 0.018
0.007 62 (24.4) 15 (17.7) 0.232
0.139 91 (35.8) 29 (34.1) 0.794
0.642 77 (30.3) 23 (27.1) 0.585
0.0001 121 86 112 73 0.395
0.155 149 (58.7) 41 (48.2) 0.102
0.219 7 (2.8) 3 (3.5) 0.717
0.014 9.2 5.6 11.6 8.3 0.019
0.049 54 (21.3) 30 (35.3) 0.014
0.121 18 (7.1) 9 (10.9) 0.349
0.314 55 15 57 13 0.150
0.179 44 (17.3) 10 (11.8) 0.304
0.779 120 (47.2) 42 (49.4) 0.802
134 (52.8) 43 (50.6)
0.215 240 (94.5) 81 (95.3) 1.00
0.596 4 (1.6) 2 (2.4) 0.643
1.00 6 (2.4) 1 (1.2) 0.684
0.059 8 (3.2) 1 (1.2) 0.459
0.295 5 (1.9) 1 (1.2) 1.00
0.723 9 (3.5) 5 (5.9) 0.352
0.410 33 (12.9) 12 (14.1) 0.854
0.610 19 (7.5) 9 (10.6) 0.368
1.00 2 (0.8) 2 (2.4) 0.262
1.00 5 (1.9) 3 (3.5) 0.419
1.00 6 (2.4) 4 (4.7) 0.276
0.372 3 (1.2) 6 (7.1) 0.009
0.204 10 (3.9) 7 (8.2) 0.148
0.819 29 (11.4) 7 (8.2) 0.542
0.477 10.7 8.3 8.0 7.7 0.014
0.307 56 (22.1) 19 (22.4) 1.00theAcco
a
9nd TA program allowed approximately one-half of the
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March 16, 2010:1080–90 TAVI: Multicenter Canadian Experienceatients refused for SAVR to be treated. Reducing the catheter
elivery size in the near future will increase the number of TF
ases, but a high proportion of patients will still exhibit
nappropriate iliofemoral arteries for accommodating 18-F
linical and Peri-Procedural Characteristics of theatients, Acco ding to the Occu rence ofumulative Late M rtality
Table 5
Clinical an Peri-Proc dural Charact ristics of the
Patients, According to the Occurrence of
Cumulative Late Mortality
Cumulative Late Mortality
Variables Yes (n  75) No (n  264) p Value
Baseline
Age (yrs) 82 8 81 8 0.748
Male sex 39 (52.0) 113 (42.9) 0.326
BMI (kg/m2) 25 4 26 5 0.389
Diabetes 21 (28.0) 58 (22.0) 0.226
Dyslipidemia 50 (66.7) 191 (73.3) 0.256
Hypertension 59 (78.7) 193 (73.1) 0.133
Current smokers 7 (9.3) 13 (4.9) 0.301
Chronic atrial fibrillation/flutter 33 (44.0) 82 (31.1) 0.044
Coronary artery disease 52 (69.3) 182 (69.0) 0.480
Previous myocardial infarction 46 (61.3) 127 (48.1) 0.190
Previous PCI 25 (33.3) 74 (28.0) 0.384
Prior coronary artery bypass
grafting
19 (25.3) 97 (36.7) 0.076
Cerebrovascular disease 22 (29.3) 55 (20.8) 0.118
Peripheral vascular disease 30 (40.0) 90 (34.1) 0.164
COPD 30 (40.0) 70 (26.5) 0.039
Creatinine (mol/l) 135 79 114 84 0.103
eGFR 60 ml/min 52 (69.3) 138 (52.3) 0.004
Dialysis 3 (4.0) 7 (2.7) 0.653
STS-PROM score (%) 11.7 8.1 9.3 5.8 0.004
Porcelain aorta 10 (13.3) 51 (19.3) 0.198
Frailty 19 (25.3) 66 (25.0) 0.785
Pulmonary hypertension 29 (38.7) 55 (20.8) 0.002
Severe mitral regurgitation 8 (10.7) 19 (7.2) 0.447
LVEF (%) 55 15 56 14 0.692
LVEF 40% 14 (18.7) 40 (15.2) 0.402
Peri-procedural variables
Approach
Transfemoral 40 (53.3) 122 (46.2) 0.884
Transapical 35 (46.7) 142 (53.8)
Unsuccessful procedure* 8 (10.7) 10 (3.8) 0.913
Valve embolization 2 (2.7) 5 (1.9) 0.244
Need for a second valve 2 (2.7) 7 (2.7) 0.756
Conversion to open heart
surgery
3 (4.0) 3 (1.1) 0.003
Need for hemodynamic
support
6 (8.0) 8 (3.0) 0.026
Major access site
complications
15 (20.0) 30 (11.4) 0.035
Life-threatening arrhythmias 6 (8.0) 22 (8.3) 0.856
Myocardial infarction 2 (2.7) 2 (0.8) 0.035
Stroke 2 (2.7) 6 (2.3) 0.948
Sepsis 6 (8.0) 4 (1.5) 0.002
Need for hemodialysis 4 (5.3) 5 (1.9) 0.098
Need for permanent
pacemaker
3 (4.0) 14 (5.3) 0.744
alues are expressed as n (%) or mean  SD. *Excluding procedural death.
Abbreviations as in Table 1.atheters. t0-day outcomes. The 30-day mortality rate of 10.4%
bserved in the present study was similar to the 8.6% to
1.3% mortality rate reported in previous smaller single-
enter studies that included both TF and TA approaches
7–9). The predictive factors of 30-day mortality included
aseline characteristics such as severe PH and MR and
eri-procedural variables such as the occurrence of any
omplication leading to the use of hemodynamic support.
alouf et al. (12) identified the presence of severe PH as an
mportant predictive factor of 30-day mortality in patients
ndergoing SAVR. Our results showed that severe PH also
ad a prognostic value in patients undergoing TAVI. The
resence of PH makes the patient both more prone to and
ulnerable during any procedural situation of hemodynamic
nstability and could also increase the risk of post-operative
omplications (13). Inoperable patients with symptomatic
evere AS associated with severe MR were accepted for
AVI with the objective of improving symptoms and the
xpectation of reducing the degree of MR by reducing
ressure overload and improving left ventricular remodeling
14,15). However, patients with severe MR had 3 times
reater risk of dying within the 30 days after TAVI. The
resence of severe MR might increase patient’s vulnerability
uring peri-procedural hemodynamic changes and post-
rocedural complications, as with severe PH. Further re-
earch is needed to optimize the acute results of TAVI in
atients with severe PH and/or MR and to determine both
he reversibility of these 2 conditions and the improvement
f symptoms and quality of life of these patients after TAVI.
he need for peri-procedural hemodynamic support in-
reased the risk of death at 30 days approximately 7-fold.
he hemodynamic instability leading to the need for he-
odynamic support was mainly secondary to either severe
entricular dysfunction after valvuloplasty and/or valve im-
lantation or life-threatening bleeding. Importantly, al-
hough the 30-day mortality rate was high in these patients,
pproximately two-thirds of them survived, highlighting the
otential benefits of having an extracorporeal circulation
achine and a surgical backup when performing these
rocedures. Interestingly, the STS-PROM score was unable
o identify those patients who would die within the first 30
ays, and this was consistent with previous TAVI studies
8,9). In fact, the vast majority of patients who underwent
AVI would not have been operated on in the past, and
ew predictive risk scores including specific variables for this
articular subset of patients should be developed in the
uture.
ate outcomes. The survival rate of 76% at 1-year
ollow-up was consistent with the 74% to 78% reported in
revious studies including TF and TA approaches (8,9).
mportantly, most deaths occurring during the follow-up
eriod were of noncardiac origin. The predictive factors of
umulative late death in the present study included peri-
rocedural variables such as the need for hemodynamic
upport and post-procedural sepsis, a cardiovascular condi-
ion such as PH, and noncardiac comorbidities such as
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TAVI: Multicenter Canadian Experience March 16, 2010:1080–90OPD and CKD. Chronic obstructive pulmonary disease is
frequent morbidity in elderly patients and 1 of the leading
auses of death in this population (16). Grossi et al. (17)
lready showed the long-term prognostic value of COPD in
atients undergoing SAVR. Our findings highlight the
elevance of both an accurate diagnostic and prognostic
valuation of the patients’ respiratory status before perform-
ng TAVI and a close follow-up of COPD patients so that
Figure 2 24-Month Follow-Up Survival Curves
Kaplan-Meier curves of survival and survival free of myocardial infarction (MI) and
who underwent transcatheter aortic valve implantation (TAVI) by transfemoral apprcute exacerbations can be reduced (18). Several studies oave shown that CKD is an independent predictor of late
ortality after SAVR in elderly patients (17,19,20), and
ebb et al. (9) recently reported that this comorbidity was
lso a predictor of worse outcomes in patients undergoing
AVI. The mechanisms linking CKD and late mortality in
ur study population were probably multifactorial (21).
mportantly, CKD has been associated not only with higher
ardiovascular but also with higher all-cause mortality in
at 24-month follow-up for the entire study population (A, B), for patients
C, D), and for patients who underwent TAVI by transapical approach (E, F).stroke
oach (lder people (22), and this prognostic factor should probably
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March 16, 2010:1080–90 TAVI: Multicenter Canadian Experiencee taken into account when evaluating the potential benefits
f the TAVI procedure at midterm follow-up, especially in
ery old patients with moderate to severe CKD. Finally, the
AVI approach had no prognostic value in the present
tudy. In fact, TF and TA approaches were associated with
ery similar survival rates at 1-year (TF: 75%, TA: 78%) and
-year (TF: 65%, TA: 64%) follow-up. Some previous
tudies suggested worse clinical outcomes associated with
he TA approach, but patients undergoing TA-TAVI have
een systematically associated with a higher risk profile
3–5). Himbert et al. (8) showed no prognostic value of
ither the TF or TA approach, consistent with our results,
hereas Webb et al. (9) showed that TA approach was an
ndependent predictor of late mortality. Future studies
hould further investigate the potential independent role of
pproach selection on TAVI outcomes.
orcelain aorta and frailty. Surgical aortic valve replace-
ent becomes a high-risk or even a prohibitive procedure in
atients in whom the ascending aorta cannot be clamped,
ecause of extensive calcification due to the risk of both
erebral embolism and the impossibility of safe aortic
issection and clamping (23,24). Approximately 20% (5% to
Figure 3 24-Month Follow-Up Survival Curves
in Porcelain Aorta and Frail Patients
Kaplan-Meier curves of survival at 24-month follow-up for
patients with porcelain aorta (A) and frailty (B) as comorbidities.3%) of the patients undergoing TAVI are diagnosed with aorcelain aorta (1–9), and the present study is the first to
valuate the procedural and late outcomes in this specific
igh-risk group of patients. Of high clinical relevance, the
troke rate was relatively low (1.6%), with no differences
ompared with the rest of the study population. However,
he need for a second valve tended to be more frequent in
his group of patients, probably reflecting a higher incidence
f valve malposition due to either difficulty in valve posi-
ioning or valve displacement during balloon inflation in the
resence of a highly calcified aorta. Although STS-PROM
cores were lower, 30-day mortality remained similar to that
f the rest of the study population, pointing out the high
isk of this group of patients. However, those patients who
urvived the procedure had a relatively low late mortality,
eading to a survival rate of 86% at 1-year follow-up. These
esults support further research into the role of TAVI for
he treatment of patients with porcelain aorta.
Older age and frailty have been among the main reasons
or considering a high (up to 33%) proportion of elderly
atients diagnosed with severe symptomatic aortic stenosis
s inoperable (10). Approximately one-half of the frail
atients also had other comorbidities leading to a high
TS-PROM score, but those patients with a lower STS-
ROM score refused for SAVR because of frailty exhibited
imilar 30-day mortality rates as those of the rest of the
tudy population, suggesting that frailty remains per se an
mportant risk factor in patients undergoing TAVI. Further
esearch will be of major importance in improving identifi-
ation and management of frail patients undergoing TAVI
s well as in determining the benefits of TAVI in this
articular subset of patients.
tudy limitations. Although the data were prospectively
ollected in each of the participating centers, there was
o pre-specified case report form designated for the
urpose of this study. However, the fact that the cases
ere presented with a similar presentation format in a
eekly conference call ensured data uniformity and par-
ially compensated for this limitation. The diagnosis of
orcelain aorta and frailty was subjective and based on the
udgment of the physician in charge of each patient. This
as partially compensated, because patients were evalu-
ted by at least 2 cardiac surgeons agreeing on the
iagnosis and were presented in a weekly conference call
n which investigators of other centers also had to agree
n the diagnosis. However, further research is needed to
rovide an objective and reproducible evaluation of these
important criteria for inoperability.
onclusions
he results of this large multicenter series of consecutive
atients with severe aortic stenosis at very high or prohib-
tive surgical risk showed that a TAVI program including
oth TF and TA approaches was associated with compara-
le mortality as predicted by surgical risk calculators despite
very high-risk patient profile. Cardiac comorbidities (se-
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TAVI: Multicenter Canadian Experience March 16, 2010:1080–90ere PH, MR), procedural factors (need for hemodynamic
upport, sepsis), and noncardiac comorbidities (COPD,
KD) determined worse outcomes. Finally, the results of
he study suggest that TAVI might be a good alternative
or the treatment of patients with porcelain aorta and/or
railty, the 2 most common comorbidities not included in
urgical risk score calculators that determined patient’s
noperability. The prospective multicenter PARTNER
rial, which is a randomized trial and has both arms comparing
AVI with surgical therapy and medical therapy, will further
etermine the safety and efficacy of TAVI for the treatment of
he challenging group of patients with symptomatic severe
ortic stenosis at very high or prohibitive surgical risk.
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